Physician profile
Michael W Hite
NPI 1407811292
$968.91
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $745 · 2020: $111 · 2021: $114.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $327.00 | 2019-2021 | |
| Amgen INC. | $225.27 | 2019-2021 | |
| Lilly USA, LLC | $125.20 | 2019-2021 | |
| Pfizer INC. | $72.51 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $67.11 | 2019 | |
| Sanofi-Aventis U.S. LLC | $56.69 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.06 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.62 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.51 | 2021 | |
| Glaxosmithkline, LLC. | $13.32 | 2019 | |
| Allergan, INC. | $12.51 | 2019 | |
| Amarin Pharma, INC. | $11.11 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.